Telefon:
+49 (0)241 95 163 153
Fax:
+49 (0)241 95 163 155
E-Mail:
orders@antikoerper-online.de

AGL Antikörper (AA 357-387)

AGL Reaktivität: Human WB, IF Wirt: Kaninchen Polyclonal RB4976 unconjugated
Produktnummer ABIN1882062
  • Target Alle AGL Antikörper anzeigen
    AGL (Amylo-alpha-1, 6-Glucosidase, 4-alpha-Glucanotransferase (AGL))
    Bindungsspezifität
    • 8
    • 7
    • 4
    • 3
    • 2
    • 2
    • 1
    AA 357-387
    Reaktivität
    • 33
    • 1
    Human
    Wirt
    • 31
    • 2
    Kaninchen
    Klonalität
    • 33
    Polyklonal
    Konjugat
    • 14
    • 3
    • 3
    • 3
    • 2
    • 2
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    Dieser AGL Antikörper ist unkonjugiert
    Applikation
    • 18
    • 18
    • 16
    • 10
    • 2
    • 1
    • 1
    • 1
    Western Blotting (WB), Immunofluorescence (IF)
    Aufreinigung
    This antibody is prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis against PBS.
    Immunogen
    This AGL antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 357-387 amino acids from the Central region of human AGL.
    Klon
    RB4976
    Isotyp
    Ig Fraction
    Top Product
    Discover our top product AGL Primärantikörper
  • Applikationshinweise
    IF: 1:10~50. WB: 1:1000
    Beschränkungen
    Nur für Forschungszwecke einsetzbar
  • Format
    Liquid
    Buffer
    Purified polyclonal antibody supplied in PBS with 0.09 % (W/V) sodium azide.
    Konservierungsmittel
    Sodium azide
    Vorsichtsmaßnahmen
    This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
    Lagerung
    4 °C,-20 °C
    Haltbarkeit
    6 months
  • Irimia, Tagliabracci, Meyer, Segvich, DePaoli-Roach, Roach: "Muscle glycogen remodeling and glycogen phosphate metabolism following exhaustive exercise of wild type and laforin knockout mice." in: The Journal of biological chemistry, (2015) (PubMed).

    Guin, Ru, Agarwal, Ritterson Lew, Owens, Comi, Theodorescu: "Loss of glycogen debranching enzyme AGL drives bladder tumor growth via induction of hyaluronic acid synthesis." in: Clinical cancer research : an official journal of the American Association for Cancer Research, (2015) (PubMed).

    DePaoli-Roach, Tagliabracci, Segvich, Meyer, Irimia, Roach: "Genetic depletion of the malin E3 ubiquitin ligase in mice leads to lafora bodies and the accumulation of insoluble laforin." in: The Journal of biological chemistry, Vol. 285, Issue 33, pp. 25372-81, (2010) (PubMed).

    Parker, Kong, Walsh, Salajegheh, Moghadaszadeh, Amato, Nazareno, Lin, Krastins, Sarracino, Beggs, Pinkus, Greenberg: "Fast-twitch sarcomeric and glycolytic enzyme protein loss in inclusion body myositis." in: Muscle & nerve, Vol. 39, Issue 6, pp. 739-53, (2009) (PubMed).

    Tagliabracci, Girard, Segvich, Meyer, Turnbull, Zhao, Minassian, Depaoli-Roach, Roach: "Abnormal metabolism of glycogen phosphate as a cause for Lafora disease." in: The Journal of biological chemistry, Vol. 283, Issue 49, pp. 33816-25, (2008) (PubMed).

    Cheng, Zhang, Gentry, Worby, Dixon, Saltiel: "A role for AGL ubiquitination in the glycogen storage disorders of Lafora and Cori's disease." in: Genes & development, Vol. 21, Issue 19, pp. 2399-409, (2007) (PubMed).

    Horinishi, Okubo, Tang, Hui, To, Mabuchi, Okada, Mabuchi, Murase: "Mutational and haplotype analysis of AGL in patients with glycogen storage disease type III." in: Journal of human genetics, Vol. 47, Issue 2, pp. 55-9, (2002) (PubMed).

    Bao, Dawson, Chen: "Human glycogen debranching enzyme gene (AGL): complete structural organization and characterization of the 5' flanking region." in: Genomics, Vol. 38, Issue 2, pp. 155-65, (1997) (PubMed).

    Hansen, Lundin, Markussen, Thorsby: "T cell receptor usage by HLA-DQw8-specific T cell clones." in: International immunology, Vol. 4, Issue 8, pp. 931-4, (1992) (PubMed).

    Yang, Ding, Enghild, Bao, Chen: "Molecular cloning and nucleotide sequence of cDNA encoding human muscle glycogen debranching enzyme." in: The Journal of biological chemistry, Vol. 267, Issue 13, pp. 9294-9, (1992) (PubMed).

  • Target
    AGL (Amylo-alpha-1, 6-Glucosidase, 4-alpha-Glucanotransferase (AGL))
    Andere Bezeichnung
    AGL (AGL Produkte)
    Synonyme
    DDBDRAFT_0219237 antikoerper, DDBDRAFT_0234114 antikoerper, DDB_0219237 antikoerper, DDB_0234114 antikoerper, GDE antikoerper, 1110061O17Rik antikoerper, 9430004C13Rik antikoerper, 9630046L06Rik antikoerper, AI850929 antikoerper, C77197 antikoerper, amylo-alpha-1, 6-glucosidase, 4-alpha-glucanotransferase antikoerper, glycogen debranching enzyme antikoerper, glycogen debranching protein antikoerper, amylo-1,6-glucosidase, 4-alpha-glucanotransferase antikoerper, AGL antikoerper, agl antikoerper, MMAH_RS03870 antikoerper, Agl antikoerper
    Hintergrund
    AGL is a glycogen debrancher enzyme which is involved in glycogen degradation. This enzyme has two independent catalytic activities which occur at different sites on the protein: a 4-alpha-glucotransferase activity and a amylo-1,6-glucosidase activity. Mutations in the AGL gene are associated with glycogen storage disease although a wide range of enzymatic and clinical variability occurs which may be due to tissue-specific alternative splicing.
    Molekulargewicht
    174764
    NCBI Accession
    NP_000019, NP_000633, NP_000634, NP_000635, NP_000636, NP_000637
    UniProt
    P35573
    Pathways
    Cellular Glucan Metabolic Process
Sie sind hier:
Kundenservice